Pharmacological Value of Caffeine, Taurine and Arginine in Nutritional Supplements and their Relation to Well Known Socially Important Diseases
International Journal of Nutrition and Food Sciences
Volume 4, Issue 1-1, January 2015, Pages: 24-29
Received: Dec. 3, 2014; Accepted: Dec. 4, 2014; Published: Dec. 30, 2014
Views 3076      Downloads 212
Authors
Yotova Maya, Medical College, Medical University - Pleven, Pleven, Bulgaria
Kaloyanov Kaloyan, Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University - Sofia, Sofia, Bulgaria
Donchev Petar, Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University - Sofia, Sofia, Bulgaria
Pencheva Ivanka, Department of Pharmaceutical chemistry, Faculty of Pharmacy, Medical University - Sofia, Sofia, Bulgaria
Article Tools
Follow on us
Abstract
Caffeine, Taurine and Arginine are one of the most widely used supplements from people of all ages. There are lot of controversial information about their proper use and effects and side effects. Our goal is to determine the reasonable boundaries of using these supplements in healthy people and more important in people with socially important diseases like high blood pressure, diabetes and dementia.
Keywords
Caffeine, Taurine, Arginine, Dementia
To cite this article
Yotova Maya, Kaloyanov Kaloyan, Donchev Petar, Pencheva Ivanka, Pharmacological Value of Caffeine, Taurine and Arginine in Nutritional Supplements and their Relation to Well Known Socially Important Diseases, International Journal of Nutrition and Food Sciences. Special Issue:Taurine and Caffeine Supplementation in Energy Food Drinks: Uses, Side Effects and Quality Control. Vol. 4, No. 1-1, 2015, pp. 24-29. doi: 10.11648/j.ijnfs.s.2015040101.15
References
[1]
H. Tapiero, G. Mathé, P. Couvreur and K.D. Tew "L-Arginine", Biomedicine and Pharmacotherapy, 2002, 56, pp. 439–445.
[2]
Watson, R. Ross, Bioactive Dietary Factors and Plant Extracts in Dermatology. Springer Science+Business Media. 2012. pp. 74.
[3]
R.J. Huxtable, "Physiological actions of taurine". Physiol Rev, 1992, 72, pp. 101–163.
[4]
R. Lovett, "Coffee: The demon drink?", New Scientist, 2005, pp. 2518.
[5]
T. L. Whitsett, C.V. Manion, H. Dix Christensen; Cardiovascular effects of coffee and caffeine, The American Journal of Cardiology, 1984, 53, pp. 918–922.
[6]
J.E. James, Critical review of dietary caffeine and blood pressure: a relationship that should be taken more seriously, Psychosomatic medicine, 2004, 66, pp. 63-71.
[7]
J.A. Greenberg, K.V. Axen, R. Schnoll, C.N. Boozer, Coffee, Tea and diabetes: the role of weight loss and caffeine; International journal of obesity; 2005, 29, pp. 1121-1129.
[8]
G.J. Biessels, Caffeine, diabetes, cognition, and dementia; Journal of Alzheimer’s disease, 2010, 20, pp. 143-150.
[9]
C. Sallabery, F. Nunes, M.S. Costa, G.T. Fioreze, A.P. Ardais, P.H. Botton, B. Klaudat, T. Forte, D.O. Souza, E. Elisabetsky, L.O. Porciuncula, Chronic caffeine prevents changes in inhibitory avoidance memory and hippocampal BDNF immunocontent in middle-aged rats; Neuropharmacology; 2013, 64, pp.153-159.
[10]
E.B. Klaassen, R.H.M. de Groot, E.A.T. Evers, J. Snel, E.C.I. Veerman, A. J.M. Ligtenberg, J. Jolles, D. J. Veltman; The effect of caffeine on working memory load-related brain activation in middle-aged males, Neuropharmacology; 2013, 64, pp. 160–167.
[11]
G.W. Arendash, W. Schleif, K. Rezai-Zadeh, E.K. Jackson, L.C. Zacharia, J.R. Cracchiolo, D. Shippy, J. Tan, Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain β-amyloid production, Neuroscience, 2006, 142, pp. 941–952.
[12]
F. Koppelstaetter, T.D. Poeppel,C.M. Siedentopf,A. Ischebeck,M. Verius,I. Haala,F.M. Mottaghy,P. Rhomberg,S. Golaszewski,T. Gotwald,I.H. Lorenz,C. Kolbitsch,S. Felber,B.J. Krause, Does caffeine modulate verbal working memory processes? An fMRI study, NeuroImage, 2008, 39, pp. 492–499.
[13]
K.C. Hayes and E.A. ,Trautwein Modern nutrition in health and disease. In: Taurine. Lea & Febiger. 1994, pp. 477-485.
[14]
T. Bouckenooghe, C. Remacle, B. Reusens "Is taurine a functional nutrient?". Current Opinion in Clinical Nutrition and Metabolic Care, 2006, 9, pp. 728–733.
[15]
J. Brosnan, M. Brosnan, "The sulfur-containing amino acids: an overview", J Nutr, 2006, 136, pp. 1636S–1640S.
[16]
U. Warskulat, U. Flogel, C. Jacoby, H.G. Hartwig, M. Thewissen, M. W. Merx, A. Molojavyi, B. Heller-Stilb, J. Schrader and D. Haussinger, "Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised". The FASEB Journal, 2004, 18, pp. 03–0496.
[17]
M.D.J. Kerai, C. J. Waterfield, S. H. Kenyon, D. S. Asker, J. A. Timbrell, "Taurine: Protective properties against ethanol-induced hepatic steatosis and lipid peroxidation during chronic ethanol consumption in rats", Amino Acids, 1998, 15, pp. 53–76.
[18]
B. McCall, "The ultimate hangover cure?". bbc.co.uk. (2005-12-28).
[19]
A. El Idrissi, E. Okeke, X .Yan, F. Sidime, L.S. Neuwirth "Taurine regulation of blood pressure and vasoactivity", Adv. Exp. Med. Biol., 2013, 775, pp. 407–425.
[20]
C. Alford, H. Cox, R. Wescott, The effects of Red Bull Energy Drink on human performance and mood, Amino Acids, 2001, 21, pp. 139-150.
[21]
O. P. Wójcik, K. L. Koenig, A. Zeleniuch-Jacquotte, M. Costa, Y. Chen, The potential protective effects of taurine on coronary heart disease , Atherosclerosis, 2008, 1, pp. 19 – 25.
[22]
The use of taurine and D-glucurono-γ-lactone as constituents of the so-called “energy” drinks, The EFSA Journal, 2009, 935, pp. 1-31.
[23]
M.D.J. Kerai, C. J. Waterfield, S. H. Kenyon, D. S. Asker, J. A. Timbrell, "Taurine: Protective properties against ethanol-induced hepatic steatosis and lipid peroxidation during chronic ethanol consumption in rats". Amino Acids, 1998, 15, pp. 53–76.
[24]
R.J. Huxtable, "Physiological actions of taurine". Physiol Rev, 1992, 72. pp. 101–163.
[25]
C.S. Irving, B.E. Hammer, S.S. Danyluk, P.D. Klein "13C Nuclear Magnetic Resonance Study of the Complexation of Calcium by Taurine". Journal of Inorganic Biochemistry, 1980, 13, pp. 137–150.
[26]
N. Urquhart, T.L. Perry, S. Hansen, J. Kennedy, "Passage of taurine into adult mammalian brain". Journal of Neurochemistry, 1974, 22, pp. 871–872.
[27]
A. Tsuji, I, Tamai, "Sodium- and chloride-dependent transport of taurine at the blood–brain barrier", Advances in Experimental Medicine and Biology, 1996, 403, 385–391.
[28]
J. Salimäki, G. Scriba, T.P. Piepponen, N. Rautolahti, L. Ahtee, "The effects of systemically administered taurine and N-pivaloyltaurine on striatal extracellular dopamine and taurine in freely moving rats". Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 368, pp. 134–141.
[29]
M.F. Olive, "Interactions between taurine and ethanol in the central nervous system", Amino Acids, 2002, 23, pp. 345–357.
[30]
T.C. Birdsall, "Therapeutic applications of taurine", Alternative Medicine Review, 1998, 3, pp. 128–136.
[31]
R. Leon, H. Wu, Y. Jin, J. Wei, C. Buddhala, H. Prentice, J.Y. Wu, "Protective function of taurine in glutamate-induced apoptosis in cultured neurons". Journal of Neuroscience Research, 2008, 87.
[32]
A. El Idrissi, J. Messing, J. Scalia, E. Trenkner, "Prevention of epileptic seizures by taurine", Advances in Experimental Medicine and Biology, 2003, 526, pp. 515–525.
[33]
J. Jr. Dominy, J.S. Thinschmidt, J. Peris, R. Jr. Dawson, R.L. Papke, "Taurine-induced long-lasting potentiation in the rat hippocampus shows a partial dissociation from total hippocampal taurine content and independence from activation of known taurine transporters". Journal of Neurochemistry, 2004, 89, pp. 1195–1205.
[34]
T.M. Foos, J.Y. Wu, "The role of taurine in the central nervous system and the modulation of intracellular calcium homeostasis", Neurochemical Research, 2002, 27, pp. 21–26.
[35]
W. Stummer, A.L. Betz, P. Shakui, R.F. Keep, "Blood–brain barrier taurine transport during osmotic stress and in focal cerebral ischemia". Journal of Cerebral Blood Flow and Metabolism, 1995, 15, pp. 852–859.
[36]
T. Ide, M. Kushiro, Y. Takahashi, K. Shinohara, S. Cha, "mRNA expression of enzymes involved in taurine biosynthesis in rat adipose tissues, Metabolism: Clinical and Experimental, 2002, 51, pp. 1191-1197.
[37]
N. Tsuboyama-Kasaoka, C. Shozawa, K. Sano, Y. Kamei, S. Kasaoka, Y. Hosokawa, O. Ezaki, "Taurine (2-aminoethanesulfonic acid) deficiency creates a vicious circle promoting obesity". Endocrinology, 2006, 147, pp. 3276–3284.
[38]
T.R. Green, J.H. Fellman, A.L. Eicher, K.L. Pratt, "Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils", Biochimica et Biophysica Acta, 1991, 1073, pp. 91–97.
[39]
H. Gürer, H. Ozgünes, E. Saygin, N. Ercal, "Antioxidant effect of taurine against lead-induced oxidative stress", Archives of Environmental Contamination and Toxicology, 2001, 41, pp. 397–402.
[40]
J. Das, J. Ghosh, P. Manna, P.C. Sil, "Taurine provides antioxidant defense against NaF-induced cytotoxicity in murine hepatocytes", Pathophysiology, 2008, 15, pp. 181–190.
[41]
M. Sinha, P. Manna, P.C. Sil, "Taurine protects the antioxidant defense system in the erythrocytes of cadmium treated mice". BMB Reports, 2008, 41, pp. 657–663.
[42]
M. Zhang, I. Izumi, S. Kagamimori, S. Sokejima, T. Yamagami, Z. Liu, B. Qi, "Role of taurine supplementation to prevent exercise-induced oxidative stress in healthy young men". Amino Acids, 2004, 26, pp. 203–207.
[43]
T. Yanagita, S.Y. Han, Y. Hu, K. Nagao, H. Kitajima, S. Murakami, "Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells", Lipids in Health and Disease, 2008, 7, pp. 38.
[44]
M. Zhang, L.F. Bi, J.H. Fang, X.L. Su, G.L. Da, T. Kuwamori, S. Kagamimori, "Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects". Amino Acids, 2004, 26, pp. 267–271.
[45]
MJ. Choi, J.H. Kim, K.J. Chang, "The effect of dietary taurine supplementation on plasma and liver lipid concentrations and free amino acid concentrations in rats fed a high-cholesterol diet". Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, 2006, 583, pp. 235–242.
[46]
Y.J. Xu, A.S. Arneja, P.S. Tappia, N.S. Dhalla, The potential health benefits of taurine in cardiovascular disease. Experimental & Clinical Cardiology, 2008, 13, pp. 57-65.
[47]
G.F. Marchesi, A. Quattrinui, O. Scarpino, R. Dellantonio, Therapeutic effects of taurine in epilepsy: a clinical and polyphisiographic study, Riv Patol Nerv Ment, 1975, 96, pp.166-184.
[48]
F. Li, O.I. Abatan, H. Kim, D. Burnett, D. Larkin, I.G. Obrosova, M.J. Stevens, "Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats", Neurobiology of Disease, 2006, 22, pp. 669–676.
[49]
R. Pop-Busui, K.A. Sullivan, C. Van Huysen, L. Bayer, X. Cao, R. Towns, M.J. Stevens "Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits", Exp Neurol, 2001, 168, pp. 259–272.
[50]
N. Yutaka, A. Minami, N. Harada, S. Sakamoto, Y. Niwa, M. Ohnaka, "Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes", American Journal of Clinical Nutrition, 2000, 71, pp. 54–58.
[51]
C. Brøns, C. Spohr, H. Storgaard, J. Dyerberg, A. Vaag. "Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus, European Journal of Clinical Nutrition, 2004, 58, pp. 1239–1247.
[52]
Q.D. Wu, J.H. Wang, F. Fennessy, H.P. Redmond, D. Bouchier-Hayes, "Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis", The American journal of physiology, 1999, 277, pp. 1229–1238.
[53]
D. Verzola, M.B. Bertolotto, B. Villaggio, L. Ottonello, F. Dallegri, G. Frumento, V. Berruti, M.T. Gandolfo, G. Garibotto, G. Deferran, "Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells", Journal of investigative medicine: the official publication of the American Federation for Clinical Research, 2002, 50, pp. 443–451.
[54]
S. L. Gage, A. Nighorn, The role of nitric oxide in memory is modulated by diurnal tim, Front Syst Neurosci, 2014, 8, pp. 59.
[55]
M. Rushaidhi, Y. Jing, J.T. Kennard, N.D. Collie, J.M. Williams, H. Zhang, P. Liu, Аging affects L-arginine and its metabolites in memory-associated brain structures at the tissue and synaptoneurosome levels, Neuroscience, 2012, 3, 21-31.
[56]
T. Schön, D. Elias, F. Moges, E. Melese, T. Tessema, O. Stendahl, S. Britton, T. Sundqvist, Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis. Eur Respir J, 2003, 21, pp. 483-488.
[57]
J.A. Kanaley, Growth hormone, arginine and exercise, Curr Opin Clin Nutr Metab Care, 2008, 11, pp. 50-54.
[58]
M.A. Van Bokhorst-De Van Der Schueren, J.J. Quak, B.M. Von Blomberg-van der Flier, D.J. Kuik, S.I. Langendoen, G.B. Snow, C.J. Green, P.A. Van Leeuwen, Effect of perioperative nutrition, with and without arginine supplementation, on nutritional status, immune function, postoperative morbidity, and survival in severely malnourished head and neck cancer patients, Am J Clin Nutr, 2001, 73, pp. 323-332.
[59]
S. Aiko, Y. Yoshizumi , T. Ishizuka, T. Horio, T. Sakano, I. Kumano, N. Kanai, T. Maehara, Enteral immuno-enhanced diets with arginine are safe and beneficial for patients early after esophageal cancer surgery, Dis Esophagus, 2008, 21, pp. 619-627.
[60]
J.W. Cheng, S.N. Baldwin, L-arginine in the management of cardiovascular diseases, Ann Pharmacother, 2001, 35, pp. 755-764.
[61]
P.H. Tsai, T.K. Tang, C.L. Juang, K.W. Chen, C.A. Chi, M.C. Hsu, Effect of arginine supplementation on post-exercise metabolic responses, Chin J Physiol, 2009, 52, pp. 136-142.
[62]
T.J. Bivalacqua, E.K. Diner, T.E. Novak, Y. Vohra, S.C. Sikka, H.C. Champion, P.J. Kadowitz, W.J. Hellstrom, A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression, J Urol, 2000, 163, pp. 1992-1998.
[63]
T. Klotz, M.J. Mathers, M. Braun, W. Bloch, U. Engelmann, Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study, Urol Int . 1999, 63, pp. 220-223.
[64]
P.C. Rodríguez, A.C. Ochoa, Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev, 2008, 222, pp. 180-191.
[65]
C.R. Morris, S.M. Morris Jr, W. Hagar, J. Van Warmerdam, S. Claster, D. Kepka-Lenhart, L. Machado, F.A. Kuypers, E.P. Vichinsky, Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med, 2003, 168, pp. 63-69.
[66]
J.A. Little, K.P. Hauser, S.E. Martyr, A. Harris, I. Maric, C.R. Morris, J.H. Suh, J. Taylor, O. Castro, R. Machado, G. Kato, M.T. Gladwin, Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy, Eur J Haematol, 2009, 82, pp. 315-321.
[67]
E.H. Fleischmann, M.P. Schlaich, B.M. Schmidt, S. Oehmer, R.E. Schmieder, Hypercholesterolaemia and treatment with statins do not alter L-arginine-induced changes of renal haemodynamics, Nephrol Dial Transplant, 2002, 17, pp. 1758-1765.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186